Making Progress with Debridement

A discussion on necrotic tissue, the importance of removing necrotic tissue from the wound environment, methods of debridement, and the role of MEDIHONEY® dressings.
Debridement is the process of removing devitalized or necrotic (dead) tissue from a wound or wound bed until the surrounding healthy tissue is exposed, allowing the healthy tissue to granulate and advance the wound through the healing process. Debridement is indicated for any wound, acute or chronic, when necrotic tissue, foreign bodies or infected tissue is present. Necrotic tissue or foreign bodies within a wound can lead to a negative cascading effect causing the wound to become chronic. Because this effect can lead to more serious consequences, including infections such as MSRA and limb amputation, it becomes imperative that an effective wound management strategy be structured and implemented.

**Primary purposes for debridement are to:**

- Control and remove infectious materials and/or biofilm\(^1\)
- Interrupt the cycle of the chronic wound so that protease and cytokine levels more closely resemble those of the acute wound\(^2\)
- Reduce bioburden by removing the necrotic tissue that supports the growth of bacteria\(^1\)
- Facilitate visualization of the wound edges and base for accurate assessment\(^3\)
Necrotic Tissue and Necrotic Burden

Necrotic or avascular tissue is the result of an inadequate blood supply to the tissue in the wound area. It contains dead cells and debris that is a consequence of the dying cells.4

There are different types of necrotic tissue including eschar and slough. Avascular tissue exposed to the air will form a hard black crust known as eschar. If kept moist, avascular tissue will appear brown, yellow or gray and soft, flimsy or stringy. This tissue is called slough. Slough is fibrinous tissue consisting of fibrin, bacteria, intact leucocytes, cell debris, serous exudates and DNA. After eschar is debrided, slough may be present as the wound is not completely clean. Thereafter, if a moist wound environment is not maintained, continued exposure to air may dessicate remaining slough, causing eschar to reform.4, 5

Necrotic burden is the combination of necrotic tissue, excess exudate and high levels of bacteria present in dead tissue that accumulate in chronic wounds. Necrotic burden creates an altered cellular environment (elevated pH, proteases, biofilm, free radicals) which causes a cascading effect that can prolong the inflammatory phase, obstruct wound contraction and impede the reepithelialization process.2

Causes of Necrotic Burden

SKIN FAILURE6

Skin failure happens when skin and underlying tissue die due to hypoperfusion, concurrent with severe dysfunction or failure of other organ systems. Determining skin failure is currently done by gross examination of muscle mass, subcutaneous tissue thickness, wound granulation, and tissue necrosis. In addition, stratifying skin failure according to the patient’s medical condition can be useful in planning interventions and setting treatment goals.

Skin failure can be typified as acute, chronic and end-stage.

Acute skin failure occurs when skin and underlying tissue die due to hypoperfusion concurrent with a critical illness. Mortality rates range from 33% within 30 days to 73.3% within 1 year of onset of skin failure in the intensive care population.

Chronic skin failure is an event in which skin and underlying tissue die due to hypoperfusion concurrent with a chronic disease state. It typically happens more steadily over time, and in older individuals. Multiple co-morbidities combined with other age-related declines can accelerate degeneration. Deterioration of internal organs can manifest in the external organ of skin.

End-stage skin failure occurs when skin and underlying tissue die due to hypoperfusion concurrent with the end of life.
Lack of blood flow or lack of tissue perfusion can be caused by occlusion, vasoconstriction, venous hypertension, hypotension, dehydration, medications, radiation, smoking, and inability to transport O2. O2 fuels the cellular functions essential to the repair process, making it critical to wound healing. Lack of blood flow causes a decrease in oxygen, slowing or stalling the healing process.

Elevated protease activity may occur in chronic wounds and may inhibit healing by degrading extra-cellular matrix proteins, growth factors, their receptors and protease inhibitors. Elevated protease activity can potentially be reduced by lowering the pH of a wound. This also may result in increased oxygen release, enhanced destruction of abnormal wound collagen, and increased macrophage and fibroblast activity.

Non-healing wounds typically display increased reactive oxygen species (ROS). ROS are deleterious in excess amounts due to their high reactivity, which causes oxidative stress. This is associated with reperfusion injury, one of the primary factors in chronic wound development. In the chronic wound environment, ROS attack DNA, causing an accumulation of lipofuscin (which the cell cannot degrade) and DNA damage-induced cell cycle arrest. Tight regulation of ROS production and detoxification is crucial for the repair process in wounds.

An infection is the presence of replicating microorganisms invading wound tissue and causing damage to the tissue and the host. Biofilms, created in the presence of a bacteria, are complex polymicrobial communities attached to a substrate, covered with an extracellular polymeric substance (EPS). Biofilms and their causative organisms are not visible to the naked eye, and conventional swabbing is often inconclusive in identifying them. Biofilms repopulate in toxic wound environments in which cells break down and chronic inflammation occurs. This is exacerbated by the release of planktonic bacteria from the biofilm, which stimulates an inflammatory response. Persister cells can repopulate the biofilm despite antibiotic susceptibility and therapy.

Finally, external factors such as foreign bodies can complicate wound management. Debris (projectiles, splinters, glass and shrapnel), and even fragments of dressing and suture material, must be removed as they can interfere with healing.
Importance of Optimizing and Controlling the Wound Bed Environment

A wound management plan should include a thorough wound assessment and selection of products capable of addressing the specific needs of the wound. Setting goal oriented strategies to gain control over the wound environment will help get the wound back on track towards healing. Appropriate goals such as maintaining the physiologic wound environment (e.g., debridement, cleansing, prevention/management of infection) and providing systemic support (e.g., edema reduction, nutrition, hydration) are the foundation to the process.

When necrotic tissue is present, there are a number of related factors that could be the root cause of delayed healing:

- Non-resolving inflammation
- Bacterial infection or $10^6$ organisms per gram of wound tissue
- Elevated levels of proteases
- Impaired perfusion and decreased tissue oxygenation or oxidative stress

Removal of necrotic tissue is therefore fundamental to allowing the wound to progress and has many beneficial effects. Proper debridement removes and reduces the barriers that impede the healing process and provides an environment that stimulates the growth of healthy tissue needed for wound healing.

Defining Stalled Wounds

Stalled wounds are generally considered those that do not heal at least 15% in two weeks. For example:

- Pressure ulcers that do not progress at least 39% in two weeks may not heal in a timely fashion
- Venous leg ulcers that do not heal at least 30% in two weeks will probably not heal in six months
- Diabetic ulcers that do not heal 30% in two weeks have only a 9% chance of healing in three months

Goal

Prepare the wound bed and promote moist wound healing.

Time Management

Proper wound bed preparation is essential to promoting the wound healing process. Utilizing the Time Management protocol will help to keep that wound on track.
Types of Debridement

The standard methods of debridement are autolytic, mechanical, enzymatic, sharp and biologic. The method of debridement used, often depends on the amount of necrotic tissue present in the wound bed, the extent of the wound, and the patient’s medical history and overall condition. Clinicians sometimes use more than one debridement method in conjunction in order to achieve the most successful removal of necrotic tissue.

**Autolytic debridement** uses the body’s own enzymes and moisture to re-hydrate, soften and finally liquefy eschar and slough. During autolysis, enzymes present in the wound have the effect of liquefying non-viable tissue. Clinicians foster autolytic debridement by utilizing moist wound dressings. By maintaining a moist wound environment, the body is able to use its own processes to eliminate necrotic tissue. Autolytic debridement can be achieved with the use of occlusive or semi-occlusive dressings which maintain wound fluid in contact with the necrotic tissue. It is virtually painless for the patient and safe, yet is generally slower than other forms of debridement. It can be used on its own, after surgical debridement, or in conjunction with enzymatic or mechanical debridement.

**Mechanical debridement** is a process in which force is exerted on the necrotic tissue to rip, pull, push or abrade away the devitalized tissue from the healthy tissue. Mechanical debridement is often non-selective and may remove or cause damage to healthy tissue as well as necrotic tissue. Examples of mechanical debridement include wet-to-dry dressings, wound irrigation, pulsatile lavage, whirlpool, contact ultrasound and scrubbing the surface with gauze. Wet-to-dry dressings do not provide a moist wound healing environment and are not optimal for wound care once the wound is free of necrotic tissue.

**Sharp debridement** is the removal of devitalized tissue by a skilled clinician, typically using a scalpel, scissors, curette or other sharp instrument. Clinicians use conservative sharp debridement to remove loosely adherent nonviable tissue at the bedside or in a clinical setting. Surgical debridement is done by a physician usually in the operating room, under anesthesia, with instruments and/or a laser when the tissue removal needs are extensive, or when the patient has a serious infection associated with the wound. Although sharp debridement is fast, it is non-selective and can be very painful to the patient.

**Enzymatic debridement**, or chemical debridement, makes use of certain enzymes and other compounds to dissolve necrotic tissue. It requires a prolonged period of enzyme activity, and a moist wound environment with appropriate pH and temperature. Enzymes are inactivated by metals in some wound care products (silver, zinc). The enzyme used in the U.S., collagenase, digests collagen in necrotic tissue by dissolving the collagen “anchors” that secure the avascular tissue to the wound bed. Collagenase has been shown to be most active within a pH range of 6 to 8.

**Biologic debridement** uses maggots grown from the sterilized eggs of *Lucilia sericata*. The larvae are placed in the wound bed, where it is theorized that they secrete proteolytic enzymes that break down necrotic tissue, which they then ingest. This is considered an option when the patient is not a surgical candidate and has not responded to other methods of debridement.

**Continual vs. intermittent debridement**

It has been found that rates of healing increase when wounds are debrided more frequently. With the increased knowledge of biofilms and their ability to repopulate, as well as the damaging effects of elevated proteases (MMP’s) of the chronic wound, more focus has been placed on continual debridement vs. single or intermittent debridement.

Continual debridement provides a consistent action of removing necrotic tissue from the wound bed over a period of time, unlike single or intermittent methods. The ability to provide continual and consistent removal of necrotic tissue helps to create an optimal environment for healing and allows for less disruption to the wound bed.
The Role of MEDIHONEY®

The overall goal for wound bed preparation is to remove factors that delay healing. These factors in a stalled or chronic wound include necrotic tissue and altered levels and composition of wound exudates.

MEDIHONEY® dressings, containing Active Leptospermum Honey (ALH), address factors that cause delayed healing in chronic wounds. As demonstrated in multiple RCTs and 100s of clinical papers, ALH helps to jump start wounds and promote autolytic debridement due to its multiple mechanisms of action. MEDIHONEY®’s osmotic effect addresses multiple aspects of debridement quickly for optimal patient care. The high sugar content of MEDIHONEY® aids in the increased flow of fluid to support the continual cleansing of the wound environment, helping to remove devitalized or necrotic tissue through an osmotic effect. Additionally, the low pH of MEDIHONEY® helps to lower the pH levels within the wound environment, which has been shown to have wound healing benefits.

1. AUTOLYTIC DEBRIDEMENT
   During autolysis the body breaks down tissue or cells. A moist environment, created by ALH dressings, aids the body’s own process of moisturizing and re-hydrating, thus loosening and liquefying necrotic tissue.

2. HIGH OSMOTIC POTENTIAL
   ALH creates an osmotic effect, which occurs when the high sugar content of honey facilitates movement of fluid from deeper tissue toward the wound surface. The increased flow of fluid helps the body’s natural processes to cleanse the wound, removing debris and necrotic tissue.

3. REDUCTION IN pH
   The failure of a chronic wound to heal has been correlated with alkaline pH levels. The surface pH of chronic wounds has been reported to range from 7.15 to 8.94. ALH has a low pH of 3.5 – 4.5, which impacts the wound helping to reduce the pH of the wound environment. Lowering the pH can help aid the body’s natural reparative processes that support the removal of dead tissue and wound healing.

High Osmolarity

Low pH Level
Evidence Supporting the Use of MEDIHONEY®

Debridement of lower extremity wounds with ALH
Becky Strilko RN, BSN, CWOCN, APN; Chris Barkauskas RN, BA, CWOCN, APN;
Andrea McIntosh, RN, BSN, CWOCN, APN, Silver Cross Hospital, Joliet, IL
Poster Presentation, April 2010, Orlando, FL

CLINICAL ISSUE
Topical products containing papain, used for removal of necrotic tissue, control of inflammation, reduction of wound odor, and rehydration of the skin, are no longer approved for use in the United States. With the loss of papain-urea based debridement agents, there was a need to find a safe and cost-effective alternative for debridement of non-viable tissue and for wound bed preparation.

INCLUSION CRITERIA
Five patients were asked to participate in an open label pilot study. Selection criteria were limited to lower extremity ulcers with a minimum of 50% devitalized tissue. Active Leptospermum Honey (ALH) has experienced increased attention in the literature as an effective agent to promote autolytic debridement. Many patients in the outpatient setting are not candidates for surgical debridement.

OUTCOME
To determine the efficacy of this product for debridement of devitalized tissue as an adjunct to a successful wound treatment program.

TREATMENT PROTOCOL
In each case an ALH calcium alginate dressing was applied to non-viable tissue and covered with an absorbent cover dressing. Dressings were changed every other day or one to two times per week or as needed for strike-through. Wound photography was performed on a weekly basis to document progression of debridement.

RESULTS
Dressings with ALH demonstrated the ability to promote debridement of necrotic tissue for five patients with lower extremity non-healing wounds. Several patients who were unable to tolerate hydrogel therapy reported improved dressing tolerance with the use of ALH. Improvement in all wounds was documented. There was a decreased percentage of non-viable tissue, increased percentage of granulation tissue, and increased dressing tolerance. The investigators confirmed that ALH dressings were an effective, first-line choice for debridement and wound bed preparation for these cases.

CONCLUSION
Debridement is a vital part of the successful management of chronic wounds. ALH’s ability to effectively aid debridement was observed in this group of five patients with differing wound types. Additional improved dressing tolerance were noted. The dressings were easy to use and well received by caregivers and patients. As a result ALH dressings are considered an adjunctive therapy for successful wound treatment in our program. Further studies are indicated.

CASE 1 - VENOUS ULCER
A 63 year-old female with a history of venous ulcer disease and Sjögren’s syndrome presented with three full thickness, non-healing ulcers of the right posterior leg. She reported being “terrified” of surgical intervention and steadfastly refused sharp debridement. Persistent, consistent “bad” pain was reported as 4-6 on a 0-10 visual analog scale. Medications included hydrochlorothiazide and propoxyphene napsylate as needed for pain. Previous treatments with triple antibiotic ointment and papain-urea-chlorophyllin complex ointment were ineffective for the promotion of wound healing. Initially, the wounds measured 1.0 cm x 1.0 cm, 5.0 cm x 2.0 cm x 0.2 cm, and 1.5 cm x 1.5 cm with scant exudates and 100% eschar; hydrogel therapy was prescribed to promote autolytic debridement. Increased pain was noted with hydrogel therapy (6-8 on a 0-10 visual analog scale). ALH calcium alginate was initiated on 9/15/2009, covered with an absorbent cover dressing and changed one to two times per week. Gradual wound improvement was noted; the patient reported, “The dressings are natural and I did not need surgical debridement.”
CASE 2 - PRESSURE ULCER

An 89 year-old male with a history of coronary artery bypass graft, congestive heart failure, atrial fibrillation, chronic renal failure, and gout presented to the wound care center with an unstageable pressure ulcer on the left heel. The patient was taking the following medications: amlodipine besylate, levothyroxine sodium, niacinamide, valsartan, finasteride, allopurinol, furosemide, simvastatin, terazosin hydrochloride, and clonidine hydrochloride. Previous treatment with hydrogel therapy to promote debridement was ineffective. ALH calcium alginate dressings were initiated on 2/02/2010, covered with an absorbent cover dressing and changed one to two times per week. Within one week progress toward debridement was noted.

CASE 3 - TRAUMATIC WOUND

A 53 year-old female with a history of hypertension, hyperlipidemia and bipolar disorder sustained a traumatic wound on the left anterior tibial region in a motor vehicle accident in May of 2008. Prior topical antimicrobial therapy (silver sulfadiazine) was ineffective for the promotion of wound healing. Her medications included valproic acid, bupropion hydrochloride, a multivitamin, and zinc supplement. She presented to the wound care center on 9/24/2009 with a full thickness wound with 90% slough and 10% granular tissue with a moderate amount of serosanguinous exudates. ALH calcium alginate was initiated, covered with compression bandaging and changed once per week. Within one week slough was eradicated, exudates decreased; the patient reported the dressings were “comfortable”. A skin graft was performed for final wound closure.

CASE 4 - TRAUMATIC WOUND

A 60 year-old healthy male taking no medications sustained two full thickness wounds on the right patella from a motorcycle accident. Initial surgical debridement was performed. He presented to the wound center two weeks later on 10/13/2009 with two full thickness wounds with 100% granulation tissue. Hydrogel therapy was prescribed to promote moist wound healing. One week later the base of each wound was covered with 90% slough, moderate amounts of wound exudates were noted. ALH calcium alginate dressings were initiated, covered with an absorbent cover dressing and changed every other day. The patient reported complete healing was achieved by week six.

CASE 5 - TRAUMATIC WOUND

A 77 year-old female with hypertension and COPD sustained an injury to her right lateral leg on 12/15/2009. The patient was taking the following medications: fluticasonepropionate/salmeterol inhalation powder, multivitamin, tiotropium bromide, albuterol sulfate, furosemide, diiltiazem hydrochloride, prednisone, and travoprost ophthalmic solution. She presented to the wound center on 1/21/10 with a 5 week-old full-thickness wound surrounded by erythema and edema. The wound measured 6.0 cm long x 2.5 cm wide x 0.3 cm deep with minimal exudates. The base of the wound was completely covered with slough (50%) and eschar (50%). Previous treatments with topical antimicrobial therapy, including silver sulfadiazine x 1 week and silver wound gel x 1 week, were ineffective for the promotion of wound healing. ALH calcium alginate dressings were initiated on 1/27/2010, covered with an absorbent conforming gauze and secured with an adherent cohesive bandage once weekly. Within two weeks slough, eschar, and erythema were decreased.
PURPOSE/RATIONALE
Since ALH has multiple properties that address many common, underlying causes of non-healing wounds, it was chosen for use on several wound types to evaluate its therapeutic effects.

INCLUSION CRITERIA
The dressing was used on two patients with chronic non-healing wounds of varying etiologies, including rheumatoid ulceration and a stage IV sacral pressure ulcer. Patients also had multiple co-morbidities. The presence of one or more wounds was causing great pain and discomfort for each patient.

TREATMENT PROTOCOL
Patients were selected to receive ALH dressings for their reported wound healing and debriding effects. ALH dressings were applied, covered with an absorbent cover dressing, and changed daily, every other day, or more frequently if needed for strike-through.

RESULTS
In each case significant wound improvement was noted as demonstrated by decreased slough and increased healing. ALH dressings were easy to use, economical, effective, and well tolerated by each patient, subsequently improving life quality.

CONCLUSION
Choosing appropriate dressings and treatment modalities for individuals with chronic, non-healing wounds is challenging due to many underlying, causative factors. The use of dressings with ALH simplified the decision process. Patients in this study, with multiple co-morbidities and various wound types, saw a reduction in slough, and an increase in healing. As a result, ALH has become this clinician’s product of choice when there is a need to address the changing wound environment and multiple underlying causes of non-healing wounds. Further studies are indicated.
CASE 1 - RHEUMATOID ARTHRITIS
A 53 year-old male with a history of rheumatoid arthritis, morbid obesity, myocardial
injury, and hepatitis C was admitted to the hospital with a new diagnosis of esophageal
cancer. He was referred for an evaluation for a foot wound that he had for two and half
years. Prior treatments including silver calcium alginate dressings and compression
bandaging were ineffective. The patient was evaluated by rheumatology, however
he refused systemic therapy for the rheumatoid ulcer; chemotherapy for esophageal
cancer was in progress. ALH paste was initiated on 5/04/2009, covered with an
absorbent calcium alginate dressing, and secured with conforming gauze bandage.
Compression bandaging was refused for edema management. Complete healing was
achieved by 9/21/2009, despite continual chemotherapy for esophageal cancer.

CASE 2 - PRESSURE ULCER
A 56 year-old female with a history of abdominal compartment syndrome, cirrhosis of the
liver, acute pancreatitis, congestive heart failure, malnutrition and hepatic encephalopathy,
developed a sacral pressure ulcer after an episode of ischemia. Initially the ulcer
presented as deep tissue injury which then evolved to a stage IV pressure ulcer. The
patient was not a candidate for surgical debridement and progress with alternative
debridement methods was slow. On 4/10/2009 ALH paste was initiated, and covered with
an absorbent calcium alginate dressing daily. Minimal sharp debridement was performed
as needed to remove loosened necrotic slough tissue. Complete healing was achieved
with only small scab by 8/10/2009.
### References:

A Guideline for Care

MEDIHONEY® Dressing Application and Removal

- Wash hands thoroughly
- Apply gloves
- Assess the wound. Look for signs of healing. Also look for any signs of increased redness, pain, swelling, or heat within or around the wound*
- Cleanse the wound and skin around the wound with sterile saline, sterile water, or other safe wound cleansers
- Dry the skin around the wound by patting gently with gauze
- Protect the skin around the wound to avoid maceration. Apply a skin protectant barrier wipe or barrier ointment. (An initial increase in exudates may occur as a result of the highly osmotic effect of MEDIHONEY®)
- Choose a MEDIHONEY® dressing that is appropriate for the amount of drainage. (MEDIHONEY® Paste or MEDIHONEY® Gel for light to moderate exudates, wounds that are hard to dress, or those that require a wound gel or paste; MEDIHONEY® HCS for dry to moderate exudates that are superficial to partial thickness wounds; MEDIHONEY® Calcium Alginate dressing for moderate to heavy exudates; MEDIHONEY® Honeycolloid dressing for light to moderate exudates)
- Apply the appropriate MEDIHONEY® dressing to fit the wound. The MEDIHONEY® Calcium Alginate and Non-adhesive HCS or Honeycolloid can be cut to fit within the wound edges.
- Apply an absorbent cover dressing (XTRASORB® super absorbent dressings are recommended due to the highly osmotic effect of MEDIHONEY®)
- Dressing change: Remove the dressing gently. If the dressing is difficult to remove, moisten with saline or water. Discard the old dressing in a disposal bag.

* The healthcare provider should be notified if the wound worsens. Report increased redness, pain, swelling, or heat on or around the wound.

CONTRAINDICATIONS

Do not use MEDIHONEY®:

- On third degree burns
- With patients that have a known sensitivity to honey or any other component parts specific to each dressing (please see package insert for more information).
- To control heavy bleeding

PRECAUTIONS

- If the dressing is not easily removed, soak with sterile saline or water until it is removed without difficulty.
- Due to the dressing’s low pH, some patients may notice a slight transient stinging. If stinging does not stop or persists and cannot be managed with an analgesic, remove dressing, cleanse area, and discontinue the use of MEDIHONEY® dressing.
- During initial use of the dressing (depending on wound exudate levels, interstitial fluid, and edema surrounding the wound), the dressings high osmotic potential may contribute to increased exudate, which could lead to maceration if the excess moisture is not managed appropriately. Manage additional moisture by adding an absorptive cover dressing and/or adjusting the frequency of dressing change. Protect the peri-wound skin by applying a skin barrier protectant to the surrounding skin.
- During the healing process it is common for non-viable tissue to be removed from the wound resulting in an initial increase in wound size. Although an initial increase in wound size may be attributed to the normal removal of non-viable tissue, consult a healthcare professional if the wound continues to grow larger after the first few dressing changes.
# MEDIHONEY® Ordering Information

<table>
<thead>
<tr>
<th>Order Code</th>
<th>Description</th>
<th>Packaging unit/Case</th>
<th>HCPCS*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gel</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31805</td>
<td>0.5 oz tube</td>
<td>10/box, 4 boxes/case</td>
<td>A4649</td>
</tr>
<tr>
<td>31815</td>
<td>1.5 oz tube</td>
<td>1/box, 12 boxes/case</td>
<td>A4649</td>
</tr>
<tr>
<td><strong>HCS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-adhesive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31622</td>
<td>2.4&quot; x 2.4&quot;</td>
<td>10/box, 5 boxes/case</td>
<td>A4649</td>
</tr>
<tr>
<td>31644</td>
<td>4.33&quot; x 4.33&quot;</td>
<td>10/box, 5 boxes/case</td>
<td>A4649</td>
</tr>
<tr>
<td>31688</td>
<td>8&quot; x 8&quot;</td>
<td>5/box, 4 boxes/case</td>
<td>N/A</td>
</tr>
<tr>
<td>31612</td>
<td>8&quot; x 12&quot;</td>
<td>2/box, 5 boxes/case</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Fenestrated - Non-adhesive</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31618</td>
<td>1.8&quot; x 1.8&quot;</td>
<td>10/box, 5 boxes/case</td>
<td>A4649</td>
</tr>
<tr>
<td><strong>Adhesive</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31722</td>
<td>2.8&quot; x 2.8&quot;</td>
<td>(4.3&quot; x 4.3&quot; with adhesive border)</td>
<td>A4649</td>
</tr>
<tr>
<td>31744</td>
<td>4 ½&quot; x 4 ½&quot;</td>
<td>(6&quot; x 6&quot; with adhesive border)</td>
<td>A4649</td>
</tr>
<tr>
<td><strong>Calcium Alginate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31012</td>
<td>¾&quot; x 12&quot;</td>
<td>5/box, 4 boxes/case</td>
<td>A4649</td>
</tr>
<tr>
<td>31022</td>
<td>2&quot; x 2&quot;</td>
<td>10/box, 10 boxes/case</td>
<td>A4649</td>
</tr>
<tr>
<td>31045</td>
<td>4&quot; x 5&quot;</td>
<td>10/box, 5 boxes/case</td>
<td>A4649</td>
</tr>
<tr>
<td><strong>Honeycolloid™</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-adhesive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31222</td>
<td>2&quot; x 2&quot;</td>
<td>10/box, 10 boxes/case</td>
<td>A4649</td>
</tr>
<tr>
<td>31245</td>
<td>4&quot; x 5&quot;</td>
<td>10/box, 5 boxes/case</td>
<td>A4649</td>
</tr>
<tr>
<td><strong>Adhesive</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31422</td>
<td>2&quot; x 2&quot;</td>
<td>(3½&quot; x 3½&quot; with adhesive border)</td>
<td>A4649</td>
</tr>
<tr>
<td>31445</td>
<td>4 ½&quot; x 4 ½&quot;</td>
<td>(6&quot; x 6&quot; with adhesive border)</td>
<td>A4649</td>
</tr>
<tr>
<td><strong>Paste</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31505</td>
<td>0.5 oz tube</td>
<td>10/box, 4 boxes/case</td>
<td>A4649</td>
</tr>
<tr>
<td>31515</td>
<td>1.5 oz tube</td>
<td>1/box, 12 boxes/case</td>
<td>A4649</td>
</tr>
<tr>
<td>31535</td>
<td>3.5 oz tube</td>
<td>1/box, 12 boxes/case</td>
<td>A4649</td>
</tr>
</tbody>
</table>

*Refer to www.dmepdac.com for the most current HCPCS coding of MEDIHONEY® surgical dressings.

Pair MEDIHONEY® with our super absorbent cover dressing, XTRASORB®. It’s osmotic gradient pulls exudate to the back of the dressing and converts it into a gel, locking it away - even under compression!